A Randomized, Placebo-Controlled Trial of Thymosin-α1 and Lymphoblastoid Interferon for Hbeag-Positive Chronic Hepatitis B
暂无分享,去创建一个
D. Machin | E. Koay | C. Wai | A. Wee | S. Lim | S. Locarnini | S. Bowden | Y. Dan | K. Fock | D. Sutedja | Yingli Wu | Yin‐Mei Lee | S. Suresh | C. Lim | S. Ishaque
[1] N. Leung,et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. , 2005, Gastroenterology.
[2] N. Leung,et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. , 2005, Gastroenterology.
[3] V. Wong,et al. A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-2b and Lamivudine with Lamivudine Alone , 2005, Annals of Internal Medicine.
[4] V. Wong,et al. A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-2b and Lamivudine with Lamivudine Alone , 2005, Annals of Internal Medicine.
[5] G. Gerken,et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.
[6] G. Gerken,et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.
[7] Yoshiyuki Suzuki,et al. A Pilot Study of Thymosin α1 Therapy for Chronic Hepatitis B Patients , 2003 .
[8] V. Carreño,et al. Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins. , 2003, The Journal of general virology.
[9] V. Carreño,et al. Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins. , 2003, The Journal of general virology.
[10] E. Schiff,et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. , 2003, Journal of hepatology.
[11] E. Schiff,et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. , 2003, Journal of hepatology.
[12] J. Sung,et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipovoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): Week 52 analysis , 2003 .
[13] J. Sung,et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipovoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): Week 52 analysis , 2003 .
[14] P. Karayiannis. Hepatitis B virus: old, new and future approaches to antiviral treatment. , 2003, The Journal of antimicrobial chemotherapy.
[15] P. Karayiannis. Hepatitis B virus: old, new and future approaches to antiviral treatment. , 2003, The Journal of antimicrobial chemotherapy.
[16] Y. Liaw,et al. Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update * , 2003, Journal of gastroenterology and hepatology.
[17] Y. Liaw,et al. Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update * , 2003, Journal of gastroenterology and hepatology.
[18] M. Wulfsohn,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.
[19] M. Wulfsohn,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.
[20] H. Thomas,et al. Mechanisms of action of interferon and nucleoside analogues. , 2003, Journal of hepatology.
[21] H. Thomas,et al. Mechanisms of action of interferon and nucleoside analogues. , 2003, Journal of hepatology.
[22] Yoshiyuki Suzuki,et al. A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients. , 2003, Internal medicine.
[23] Yoshiyuki Suzuki,et al. A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients. , 2003, Internal medicine.
[24] A. Nanji,et al. Thymosin‐α1 and famciclovir combination therapy activates T‐cell response in patients with chronic hepatitis B virus infection in immune‐tolerant phase , 2002, Journal of viral hepatitis.
[25] A. Nanji,et al. Thymosin‐α1 and famciclovir combination therapy activates T‐cell response in patients with chronic hepatitis B virus infection in immune‐tolerant phase , 2002, Journal of viral hepatitis.
[26] A. R. Kandiloğlu,et al. Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey. , 2002, Hepato-gastroenterology.
[27] A. R. Kandiloğlu,et al. Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey. , 2002, Hepato-gastroenterology.
[28] F. Chisari,et al. Inhibition of Hepatitis B Virus Replication by Interferon Requires Proteasome Activity† , 2002, Journal of Virology.
[29] F. Chisari,et al. Inhibition of Hepatitis B Virus Replication by Interferon Requires Proteasome Activity† , 2002, Journal of Virology.
[30] H. Asakura,et al. Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. , 2002, Hepatology research : the official journal of the Japan Society of Hepatology.
[31] H. Asakura,et al. Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. , 2002, Hepatology research : the official journal of the Japan Society of Hepatology.
[32] J. Sung,et al. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta‐analysis , 2001, Alimentary pharmacology & therapeutics.
[33] J. Sung,et al. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta‐analysis , 2001, Alimentary pharmacology & therapeutics.
[34] G. Barbarini,et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. , 2001, Journal of hepatology.
[35] G. Barbarini,et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. , 2001, Journal of hepatology.
[36] C. Bréchot,et al. Inhibition of Hepatitis B Virus Replication by the Interferon-Inducible MxA Protein , 2001, Journal of Virology.
[37] C. Bréchot,et al. Inhibition of Hepatitis B Virus Replication by the Interferon-Inducible MxA Protein , 2001, Journal of Virology.
[38] A. Dhillon,et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial , 2000, Gut.
[39] A. Dhillon,et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial , 2000, Gut.
[40] E. Schiff,et al. Thymosin α1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double‐blind and placebo‐controlled study , 1999 .
[41] E. Schiff,et al. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. , 1999, Journal of viral hepatitis.
[42] E. Schiff,et al. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. , 1999, Journal of viral hepatitis.
[43] N. Leung,et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.
[44] N. Leung,et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.
[45] Y. Liaw,et al. Efficacy of thymosin α1 in patients with chronic hepatitis B: A randomized, controlled trial , 1998 .
[46] Y. Liaw,et al. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. , 1998, Hepatology.
[47] Y. Liaw,et al. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. , 1998, Hepatology.
[48] G. Dusheiko. Side effects of α interferon in chronic hepatitis C , 1997, Hepatology.
[49] David Machin,et al. Sample Size Tables for Clinical Studies , 1997 .
[50] G. Rasi,et al. Combination low‐dose lymphoblastoid interferon and thymosin α1 therapy in the treatment of chronic hepatitis B , 1996, Journal of viral hepatitis.
[51] G. Rasi,et al. Combination low‐dose lymphoblastoid interferon and thymosin α1 therapy in the treatment of chronic hepatitis B , 1996, Journal of viral hepatitis.
[52] J. Lavine,et al. Cytokine inhibition of the hepatitis B virus core promoter , 1996, Hepatology.
[53] J. Lavine,et al. Cytokine inhibition of the hepatitis B virus core promoter , 1996, Hepatology.
[54] R. Figueroa Barrios. [Chronic hepatitis]. , 1995, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.
[55] R. Figueroa Barrios. [Chronic hepatitis]. , 1995, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.
[56] A. Couroucé,et al. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. , 1994, Virology.
[57] A. Couroucé,et al. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. , 1994, Virology.
[58] P. Andersen,et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep). , 1994, Journal of hepatology.
[59] P. Andersen,et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep). , 1994, Journal of hepatology.
[60] A. Detsky,et al. Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.
[61] A. Detsky,et al. Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.
[62] M. Rugge,et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti‐HBe in chronic hepatitis type B , 1986, Hepatology.
[63] M. Rugge,et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti‐HBe in chronic hepatitis type B , 1986, Hepatology.
[64] M. Mutchnick,et al. Thymosin modulation of regulatory T cell function. , 1982, Clinical immunology and immunopathology.
[65] M. Mutchnick,et al. Thymosin modulation of regulatory T cell function. , 1982, Clinical immunology and immunopathology.